Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) had its price objective decreased by HC Wainwright from $245.00 to $220.00 in a report released on Monday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 164.11% from the company's previous close.
INBX has been the topic of a number of other reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inhibrx Biosciences in a research report on Friday, September 11th. Citigroup restated a "market perform" rating on shares of Inhibrx Biosciences in a research report on Friday, September 18th. Finally, Wall Street Zen lowered Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inhibrx Biosciences has an average rating of "Moderate Buy" and an average target price of $185.00.
View Our Latest Report on INBX
Inhibrx Biosciences Price Performance
INBX opened at $83.30 on Monday. The stock has a market capitalization of $1.23 billion, a P/E ratio of -9.19 and a beta of 4.03. The company's 50 day simple moving average is $95.27 and its 200-day simple moving average is $92.14. Inhibrx Biosciences has a one year low of $57.30 and a one year high of $155.29.
Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($2.46) earnings per share for the quarter, missing the consensus estimate of ($2.45) by ($0.01). The company had revenue of $2.00 million for the quarter, compared to analysts' expectations of $1.90 million. As a group, analysts anticipate that Inhibrx Biosciences will post -9.91 EPS for the current year.
Insider Buying and Selling
In other Inhibrx Biosciences news, Director Kimberly Manhard sold 500 shares of the stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $110.26, for a total value of $55,130.00. Following the transaction, the director owned 8,000 shares of the company's stock, valued at approximately $882,080. This represents a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Douglas Forsyth purchased 2,500 shares of the stock in a transaction dated Tuesday, September 8th. The stock was bought at an average cost of $114.65 per share, with a total value of $286,625.00. Following the completion of the purchase, the director owned 227,064 shares in the company, valued at $26,032,887.60. The trade was a 1.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 62,540 shares of company stock worth $6,347,507 and sold 1,500 shares worth $168,590. 18.26% of the stock is owned by company insiders.
Institutional Investors Weigh In On Inhibrx Biosciences
Large investors have recently bought and sold shares of the company. HighTower Advisors LLC raised its stake in shares of Inhibrx Biosciences by 1.6% in the 3rd quarter. HighTower Advisors LLC now owns 884,441 shares of the company's stock valued at $88,515,000 after purchasing an additional 13,890 shares during the period. Bank of America Corp DE acquired a new position in shares of Inhibrx Biosciences during the second quarter worth about $79,698,000. BlackRock Inc. acquired a new position in shares of Inhibrx Biosciences during the second quarter worth about $78,261,000. Parkman Healthcare Partners LLC acquired a new position in shares of Inhibrx Biosciences during the second quarter worth about $24,346,000. Finally, SummitTX Capital L.P. grew its holdings in shares of Inhibrx Biosciences by 66.3% during the first quarter. SummitTX Capital L.P. now owns 137,821 shares of the company's stock worth $9,266,000 after buying an additional 54,936 shares in the last quarter. Institutional investors own 82.46% of the company's stock.
Inhibrx Biosciences Company Profile
(
Get Free Report)
Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company's oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibrx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.
While Inhibrx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.